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Preservation of the kidney  
by carbon monoxide:  
a black swan phenomenon
Karl A. Nath1
Nakao and colleagues demonstrate that carbon monoxide added to 
organ preservation solution reduces donor-kidney injury that occurs 
after cold storage and transplantation and improves the survival of the 
recipient. These findings are important because they highlight the role of 
the cytochrome P450 system in the pathogenesis of donor-kidney injury 
and they suggest a strategy for preserving the donor kidney, namely, the 
addition of carbon monoxide to organ preservation solution.
Kidney International (2008) 74, 989–991. doi:10.1038/ki.2008.423
Carbon monoxide (CO) possesses a high 
affinity for the heme prosthetic group, the 
latter representing a defining motif for a 
family of ubiquitous and functionally 
diverse proteins. Such binding may mark-
edly impair the function of these proteins, 
and for heme proteins that subserve a vital 
function, the consequences can be lethal. 
For example, the affinity of CO for hemo-
globin is more than 200 times greater than 
that of oxygen, and in sufficiently high 
concentrations, CO vitiates the oxygen-
carrying capability of hemoglobin and 
thereby compromises the oxygenation of 
tissues. Through these and other effects, 
CO can cause acute and chronic toxicity, 
and, indeed, environmental exposure to 
CO is one of the commonest causes of 
accidental poisoning in the United States, 
and a cause for considerable and appro-
priate public concern.
Viewed from this perspective, it may 
come as a surprise that CO added to 
organ preservation solution can improve 
the function of the transplanted kidney 
and the survival of the recipient. Yet these 
remarkable findings are described in an 
important study by Nakao et al.1 (this 
issue). In addition to suggesting a strategy 
for organ preservation, these findings of 
Nakao et al.1 are a significant step in the 
steady procession of experimental studies 
demonstrating the remarkable cytoprotec-
tive properties of CO when it is present 
in relatively low concentrations.2–4 The 
initial demonstration that induction of 
heme oxygenase-1 (HO-1) can confer a 
protective response against tissue injury 
stimulated interest in HO-1 as a cytopro-
tective molecule, and in identification of 
the specific HO product and downstream 
effect of the induction of HO-1 that are 
responsible for such cytoprotection.5 
Initially, attention was directed to the 
synthesis of ferritin (an antioxidant, iron-
binding protein) and the production of 
bile pigments (antioxidant metabolites) 
as potential mechanisms.5 CO, the other 
main product of HO activity, while rec-
ognized as a vasorelaxant molecule and 
incriminated as a signaling species, was 
not considered, at the time, a cytopro-
tective molecule. This salutary property 
of CO was shown in 1999 in a landmark 
study that demonstrated that CO, at rela-
tively low concentrations (50–500 parts 
per million), protected against hyperox-
ia-induced lung injury by suppressing 
inflammation and apoptosis.6 These find-
ings presaged a groundswell of investiga-
tions demonstrating the beneficial effects 
of CO (when present in such low concen-
trations) in diverse models of tissue injury, 
and which reflected, depending on the dis-
ease model, any one or combination of the 
following properties of CO: antiapoptotic, 
anti-inflammatory, immune-suppressant, 
antithrombotic, angiogenic, antifibrotic, 
and vasorelaxant.2–4,7,8 Moreover, such 
protection was conferred not only by CO 
administered as a gas but also by novel 
CO-releasing compounds.3
The cytoprotective properties of HO-1 
were rapidly explored in the field of trans-
plantation and were observed to mitigate 
ischemia/reperfusion injury of the trans-
planted kidney, acute renal allograft rejec-
tion, and chronic allograft nephropathy; 
these protective effects were recapitulated, 
in part, by products of HO such as CO 
and/or bile pigments.7,8 Attention was 
also directed to organ preservation, an 
issue of central importance in this field, 
and one renewed by the increasing use of 
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marginal donor organs. From the moment 
of harvesting, the kidney and other donor 
organs are subjected to a series of stresses. 
Deprived of its blood supply at the time of 
procurement, flushed with a cold, artifi-
cial solution, and maintained in the cold 
for variable periods, and then subjected 
to rewarming, reoxygenation, and reper-
fusion, the kidney is nonetheless expected 
to successfully negotiate each of these 
phases such that its vitality and function 
are preserved when it is transplanted into 
the recipient. Failure to adequately with-
stand the stresses imposed by each phase 
may increase, in the short term, the risk 
for delayed graft function and acute cel-
lular rejection, and in the long term, the 
risk for chronic allograft nephropathy. 
Considerable effort is thus understand-
ably directed to optimizing solutions used 
for organ preservation.
Using an orthotopic kidney transplant 
model, Nakao et al.1 demonstrated that 
the use of a CO-containing preservation 
solution diminished oxidative injury 
and the upregulation of inflammatory 
participants in the kidney as assessed 
3 hours after transplantation; improved 
renal function and reduced histologic 
injury at 1 month after transplantation; 
and enhanced survival of the recipients 
of these kidneys over 100 days of obser-
vation in the post-transplantation period. 
To explore the basis for these effects, the 
authors drew on the long-recognized 
observation that in injured tissues, desta-
bilization of heme proteins can occur 
such that heme is released from the pro-
tein moiety to which it is bound. Heme, in 
its free, unfettered form, and in sufficient 
amounts, is toxic by virtue of its lipophilic, 
prooxidant, proinflammatory, and pro-
apoptotic properties. Heme proteins vary 
with regard to the ease with which heme 
can be freed from its linkage with protein, 
and cytochrome P450 heme proteins are 
among those considered more likely to 
do so. Cytochrome P450 heme proteins 
are abundant in the kidney, where they 
facilitate the metabolism of endogenous 
and exogenous substances; in models of 
ischemic renal injury, they are denatured 
and contribute to kidney injury by releas-
ing heme or iron, either of which can pro-
mote oxidative stress. In the present study 
by Nakao et al.,1 the addition of CO to the 
preservation fluid prevented the marked 
increase in kidney heme content and the 
degradation of kidney cytochrome P450 
observed in the transplanted kidney and 
assessed 3 hours after the onset of reper-
fusion. That heme content was increased in 
the kidneys exposed to the control preser-
vation solution and decreased when such 
solutions contained CO was corroborated 
by the observed changes in expression 
of HO-1 and 5-aminolevulinic acid syn-
thase-1 (ALAS-1): it is well established that 
the rate-limiting enzyme in heme degrada-
tion (HO-1) is induced, and the rate-lim-
iting enzyme in heme synthesis (ALAS-1) 
is suppressed, when tissue content of heme 
is increased. The authors thus suggest that, 
following the stress of cold preservation 
and transplantation, cytochrome P450 
heme proteins undergo denaturation and 
the release of heme, the latter inducing 
renal injury because of its prooxidant and 
proinflammatory effects; CO, when added 
to the preservation solution, binds to cyto-
chrome P450 enzymes, thereby stabilizing 
them and preventing their oxidative dena-
turation and the attendant increments in 
kidney heme content (Figure 1).
This pathway provides a plausible 
explanation for the observed findings. 
Germane considerations raised by these 
findings include the fate of redox-active 
iron in the donor kidney and the possi-
bility that redox-active iron in the donor 
kidney may contribute to kidney injury. It 
is also possible that oxidative stress during 
the phase of reoxygenation/reperfusion 
may be a cause, as well as a consequence, 
of destabilization of cytochrome P450. 
Furthermore, the protective effects of CO 
may also reside in mechanisms that are 
upstream of, or do not directly involve, 
stabilization of cytochrome P450. Interest-
ingly, CO can promote as well as diminish 
oxidant stress,9 and either effect of CO may 
be relevant to cytoprotection. For exam-
ple, by interacting with heme contained in 
NADPH oxidase, CO can diminish oxidant 
generation from this source. Conversely, by 
interacting with heme contained in mito-
chondrial cytochrome oxidase, CO can 
inhibit mitochondrial electron transport, 
and such inhibition of electron transport, 
as is well established, promotes the genera-
tion of oxidants. An intriguing question is 
whether low-grade oxidant generation in 
the donor kidney, induced by CO during 
cold storage, may condition the kidney 
so as to render the organ resistant to the 
surge of oxidative stress expected during 
the phase of reoxygenation/reperfusion. 
Irrespective of the mechanism underlying 
the beneficial effects of CO, the signifi-
cance of the study of Nakao et al.1 is that it 
provides a CO-based strategy for kidney 
preservation, one that is applicable to other 
organs,7 and one that may also be proffered 
by CO-releasing molecules.3
Figure 1 | Mechanisms underlying donor-kidney injury and the protective effect of 
carbon monoxide. The dashed arrow indicates an inhibitory effect of carbon monoxide on the 
degradation of cytochrome P450 heme proteins. Abbreviations: CO, carbon monoxide; ALAS-1, 
5-aminolevulinic acid synthase-1; HO-1, heme oxygenase-1.
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In his brilliant analysis, Taleb uses the 
phrase ‘black swan’ to designate those 
unusual phenomena that turn out to be 
highly influential and consequential, and 
yet were neither predicted nor antici-
pated.10 Viewed from the clinical and 
environmental perspective of CO as an 
invariant and potentially lethal toxicant, 
it would never have been predicted that, 
in much lower amounts, CO may be a pro-
tectant. Although the challenges in real-
izing the therapeutic potential of CO are 
huge and include the bedeviling truth that, 
in increasing concentrations, CO is trans-
formed from a protectant to a toxicant, 
nonetheless, the prospect that CO affords 
a therapeutic strategy for human disease 
carries, unquestionably, a high impact. CO 
as a therapeutic agent thus appears as a 
black swan. That such an exciting prospect 
exists is an indubitable testament to the 
importance of the initial demonstration 
of the cytoprotective properties of CO, 
the illuminating evidence that followed, 
and the present findings of Nakao et al.1 
demonstrating that CO may assist in pre-
serving the donor kidney.
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Animal models of sepsis  
and its complications
Mitchell P. Fink1,2,3,4
Most currently used animal sepsis models fail to adequately replicate 
the clinical problem and, therefore, have only limited utility for 
investigating pathophysiological mechanisms or testing the efficacy of 
new therapeutic agents. Recent experimental findings support this view 
and suggest that models of acute infection in mice with pre-existing 
renal dysfunction may be useful in the development pathway for new 
therapeutic agents for sepsis.
Kidney International (2008) 74, 991–993. doi:10.1038/ki.2008.442
Sepsis is a potentially life-threatening 
condition caused by infection and char-
acterized by a poorly controlled systemic 
inflammatory response.1 Severe sepsis is 
sepsis with evidence of acute organ system 
dysfunction, and septic shock is sepsis 
associated with systemic arterial hypo-
tension.1 Sepsis, severe sepsis, and septic 
shock represent a huge public-health prob-
lem; epidemiological data suggest that in 
the United States alone, there are more 
than 600,000 cases annually2,3 and more 
than 200,000 people die every year from 
severe sepsis and its complications.3
Despite the magnitude of the prob-
lem, progress in the development of bet-
ter therapeutic modalities for sepsis has 
been slow. Indeed, only one therapeutic 
agent, drotrecogin alfa (activated), also 
known as recombinant human activated 
protein C, has been shown to improve 
survival in patients with severe sepsis 
and septic shock.4 Although this agent 
has been approved by regulatory agen-
cies in the United States and elsewhere for 
the treatment of selected cases of severe 
sepsis, clinical adoption of recombinant 
human activated protein C has been rela-
tively slow, possibly because of concerns 
about its cost,5 safety,6,7 and/or efficacy.8
Clearly, there remains a need to develop 
improved therapeutic agents to ameliorate 
organ dysfunction and improve survival 
in patients with severe sepsis. Because 
it is enormously expensive to carry out 
clinical trials of new drugs or biologics 
for severe sepsis, only the most promis-
ing agents can be evaluated in this way. 
As a consequence, investigators have 
relied on various animal models of sepsis 
to evaluate the efficacy of various novel 
therapeutic strategies. But animal mod-
els provide, at best, a crude approxima-
tion of human sepsis, especially when one 
considers that outcome in the clinical set-
ting is undoubtedly influenced by myriad 
factors, including genetic background, 
therapeutic interventions and supportive 
care, age, and pre-existing medical condi-
tions. It is noteworthy, therefore, that the 
most commonly studied animal models 
of sepsis use highly inbred strains of mice 
with a consistent genetic background, 
include little or no supportive care as part 
of the protocol, and use young, previously 
healthy subjects.
Probably the most extensively stud-
ied animal models of sepsis use rodents 
(mice or rats) injected with lipopoly-
saccharide (LPS), a compound purified 
from the outer cell wall of Gram-negative 
bacteria. When rodents are injected 
intravenously or intraperitoneally with 
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